Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Current Deferred Revenue (2024 - 2025)

Aclaris Therapeutics (ACRS) has 2 years of Current Deferred Revenue data on record, last reported at $3.9 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 1.36% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, up 1.36%, while the annual FY2025 figure was $3.9 million, 1.36% up from the prior year.
  • Current Deferred Revenue reached $3.9 million in Q4 2025 per ACRS's latest filing, roughly flat from $3.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $25.8 million in Q2 2024 and bottomed at $3.8 million in Q3 2024.